| [1] |
Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemother-apy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27 [J]. J Clin Oncol,2008,26(5):778-785.
|
| [2] |
Cocquyt VF, Blondeel PN, Depypere HT, et al. Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma [J]. Eur J Surg Oncol,2003,29(4):361-367.
|
| [3] |
Cristofanilli M, GonzalezAngulo A, Sneige N, et al. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes [J]. J Clin Oncol,2005,23(1):41-48.
|
| [4] |
TubianaHulin M, Stevens D, Lasry S, et al. Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution [J]. Ann Oncol,2006,17(8):1228-1233.
|
| [5] |
Tavassoli FA, Devilee P. World Health Organization classification of tumours pathology and genetics of tumours of the breast and female genital organs [M].Lyon:IARC press, 2003:10.
|
| [6] |
Wolff AC, Hammond ME, Schwartz JN, et al. American society of clinical oncology/college of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer [J]. J Clin Oncol, 2007,25(1): 118- 145.
|
| [7] |
Eisenhauer EA, Therasse P, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J].Eur J Cancer, 2009, 45(2):228-247.
|
| [8] |
Rieber A, Brambs HJ, Gabelmann A, et al. Breast MRI for monitoring response of primary breast cancer to neo-adjuvant chemotherapy[J]. Eur Radiol, 2002,12(7): 1711-1719.
|
| [9] |
Rosen EL, Blackwell KL, Baker JA, et al. Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy [J]. AJR Am J Roentgenol, 2003,181(5):1275-1282.
|
| [10] |
Katz A, Saad ED, Porter P, et al. Primary systemic chemotherapy of invasive lobular carcinoma of the breast [J]. Lancet Oncol,2007,8(1):55-62.
|
| [11] |
Mathieu MC, Rouzier R, Llombart-Cussac A, et al. The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile[J]. Eur J Cancer,2004,40(3): 342-351.
|
| [12] |
Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes [J].Clin Cancer Res, 2007,13(8):2329-2334.
|
| [13] |
Straver ME, Rutgers EJ, Rodenhuis S, et al. The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy[J]. Ann Surg Oncol,2010, 17(9):2411-2418.
|
| [14] |
Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer [J]. J Clin Oncol,2005,23(16):3676-8365.
|